Browsing Tag
MEK inhibitors
1 post
Pasithea Therapeutics advances cancer trial after positive safety review of PAS-004
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has reached a significant milestone in its Phase 1 clinical trial of PAS-004,…